ME/CFS and Post-Exertional Malaise: Can You Raise Your Energy Ceiling, or Only Pace Around It?

TL;DR: If you have myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) or long COVID with delayed crashes after effort, the question on your mind is whether your energy ceiling can rise or if you are stuck managing around the same small tank forever. The answer is that both pacing and targeted medical treatment can move your floor up, if you do them in the right order. First, stop any fixed "add 1 minute a day" walking plan, because scheduled increases trigger crashes. Use a chest-strap heart-rate monitor and keep daily effort below your resting heart rate plus about 15 beats per minute until the crashes stop. Second, ask your doctor to test the treatable pieces routine workups skip: a 10-minute morning stand test for circulation drops, a ferritin level for iron stores (aiming above 50-75), a blood test for celiac disease, an in-lab sleep study if you wake unrefreshed, and a slow liquid trial of low-dose naltrexone toward 1.5-4.5 mg. Stabilize inside your energy limit first, treat what the workup finds, and only expand activity once your baseline holds steady.

Not long ago, a 39-year-old software engineer came to see me at Fishtown Medicine after 14 months of post-viral exhaustion. She had done everything her previous clinics asked of her: her thyroid panel was normal, her brain MRI was clear, and she had dutifully followed a physical therapy plan instructing her to walk 5 minutes in week one, 6 minutes in week two, and 7 minutes in week three. Instead of getting stronger, she paid for every walk the following afternoon with a heavy, flu-like crash that kept her in a darkened bedroom for days. Across the desk in my office, she asked the question almost every patient with myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) or long COVID eventually reaches: "Can I raise my energy ceiling at all, or am I only learning to live inside a smaller box?"

That question has a clear clinical answer, and it starts by recognizing that the conventional 7-minute visit failed you by treating post-exertional malaise like ordinary deconditioning. Raising your ceiling is possible for many patients when we reverse the sequence most exercise plans use. You do not push the ceiling up from outside your energy limit. You stabilize inside your limit first, and while your body stops crashing, we hunt down the 6 treatable medical contributors that drain the tank in the background.

Why do "add 1 minute a day" walking plans backfire in ME/CFS?

Fixed-increment exercise schedules backfire because they are graded exercise therapy (GET) in miniature, advancing your workload by the calendar while ignoring the delayed crash physiology of post-exertional malaise (PEM). In 2021, the United Kingdom's National Institute for Health and Care Excellence updated its ME/CFS guideline (NG206) and explicitly advised against any program built on fixed incremental increases in physical activity or exercise. That reversal followed years of consistent harm reports: in an analysis of patient surveys across pacing, cognitive behavioral therapy, and graded exercise, 74% of patients reported worse symptoms after graded exercise therapy, while pacing had the highest rate of improvement (44%) and the lowest rate of worsening (14%).

The physiology explains why the calendar loses to your symptoms. When someone without PEM walks an extra minute, their muscles and heart recover overnight and adapt upward. When someone with ME/CFS crosses their daily energy limit, they trigger an abnormal metabolic, immune, and vascular cascade that peaks 12 to 48 hours later, and sometimes stretches into a 2-week or 3-week flare. Adding 1 minute tomorrow before tomorrow's crash has even arrived guarantees you are stacking effort on top of an injured recovery system.

The governing framework that works is the energy envelope, developed by Leonard Jason and colleagues. Your energy envelope is the match between the energy you have available on a given day and the energy you spend across physical movement, thinking, conversation, and sensory load (light, noise, and emotional stress all draw from the same account). In Jason's cohort research on energy modulation, patients who stayed within their perceived energy envelope saw a 37.6% improvement in physical functioning and a 16.0% reduction in fatigue severity, compared with 6.0% and 2.7% for patients who kept pushing past it.

The most useful clinical lesson comes from a follow-up analysis by Brown, Khorana, and Jason in the Journal of Clinical Psychology (2011). They divided patients into 4 groups based on whether they started inside or outside their energy envelope and whether they increased or decreased their activity. Only the patients who were already stabilized inside their envelope and then increased activity achieved meaningful improvements in fatigue. Patients who were still outside their envelope and tried to increase activity gained nothing. That study is the whole argument for sequencing: stabilize inside your envelope first, let the crash cycle quiet down, and expand later.

Across controlled trials, the signal points the same direction. A 2023 systematic review and meta-analysis of 14 randomized controlled trials found that activity pacing interventions significantly reduced fatigue (Hedges' g = -0.52) and improved physical function in chronic fatigue syndrome, and a structured 6-week pacing protocol in patients with post-exertional malaise cut mean PEM crashes from 3.4 episodes per week down to 1.1 per week. A 2024 post-COVID randomized feasibility trial using symptom-titrated activity improved objective physical activity while lowering symptom scores at the same time. Because no trial has directly compared every pacing method head-to-head, scoping reviews of the pacing literature treat symptom-contingent pacing as a reasoned synthesis of physiology and trial data instead of a rigid formula.

How does heart-rate-ceiling pacing keep you out of a crash?

Heart-rate-ceiling pacing gives you a live speedometer so you can stop an activity before your cells cross from oxygen-based energy into emergency anaerobic metabolism. In healthy adults, the anaerobic threshold, the workload where your body can no longer make enough energy with oxygen alone and begins accumulating lactic acid and metabolic byproducts, stays high enough that walking down the block, showering, or folding laundry never comes close to it. In ME/CFS, that ceiling drops into the range of ordinary daily chores.

We have strong objective data on that drop. A 2019 systematic review and meta-analysis of cardiac autonomic regulation in ME/CFS found that resting heart rate runs roughly 4 beats per minute higher than in healthy controls while heart rate at the anaerobic threshold is significantly reduced. In 2024, the National Institutes of Health deep-phenotyping study in Nature Communications confirmed that post-infectious ME/CFS participants reached their anaerobic threshold at a significantly lower oxygen uptake (roughly 1.4 metabolic equivalents lower) and frequently showed chronotropic incompetence, an impaired ability of the heart rate to rise smoothly to match effort.

In a research lab, physiologists measure that threshold with a 2-day cardiopulmonary exercise test (CPET), where you ride a stationary bike to exhaustion on 2 consecutive days to document the drop in oxygen consumption on day 2. Outside of disability documentation, we rarely put patients through a 2-day CPET because the test is expensive and routinely triggers a severe crash.

Instead, we use a practical clinical rule of thumb: keep your working heart rate below your morning resting heart rate plus 15 beats per minute. If your resting heart rate in bed is 68 beats per minute, your working ceiling is roughly 83 beats per minute. When your chest strap buzzes at 83 while you are climbing the stairs or unloading the dishwasher, you sit down and let the number drop before doing the next step. I frame that "resting heart rate plus 15" number to patients for what it is: a physiologically sensible guardrail instead of a threshold proven in its own randomized trial. Even a protocol capping heart rate at 80% of the anaerobic threshold reduced but did not eliminate post-exertional malaise on its own, because cognitive effort and sensory overload can trigger a crash without moving your pulse. Still, for physical tasks, a live heart-rate ceiling is the clearest day-to-day tool we have.

Which wearables and tracking tools help with pacing?

Because your safe heart-rate window in ME/CFS is narrow, the type of sensor you wear changes how well the guardrail works. A chest-strap heart-rate monitor reads the electrical signal of each heartbeat and updates beat by beat, whereas wrist optical sensors lag behind rapid heart-rate rises during brief tasks like standing up or carrying laundry. Wrist trackers and phone camera apps do their best work over days and weeks: in an observational study of continuous activity monitoring in ME/CFS, daily step counts correlated directly with physical function scores, and a run-in period of 1 to 2 weeks lets you see your baseline fluctuations before changing anything. In a 2026 NPJ Digital Medicine study and a 2026 Sports Medicine study of long COVID, within-person rises in morning resting heart rate and drops in heart rate variability (HRV) predicted upcoming symptom crashes, giving you an early warning sign on the pillow at 7 AM to scale back the day's plans.

Guidance from the Clinic

"When someone asks me whether they can raise their energy ceiling or only manage around it, my answer is that we stop trying to push the ceiling up with willpower and start looking for the weights pressing down on it. Stabilizing inside your energy envelope stops the weekly crash cycle, and testing for orthostatic blood flow drops, low iron stores, sleep resistance, and celiac disease finds the pieces we can treat."

Figure: Crossing a lowered anaerobic threshold in ME/CFS triggers a delayed 12-to-48-hour post-exertional crash, whereas stabilizing below a chest-strap ceiling of resting heart rate plus 15 beats per minute stops the crash cycle. Once stabilized inside the energy envelope, treating the 6 high-yield medical contributors - starting with a 10-minute morning NASA Lean Test and iron repletion toward a ferritin above 50 to 75 ug/L - lifts the functional baseline.

Which treatable contributors can raise your baseline in ME/CFS?

While pacing protects your floor, raising your ceiling comes from finding and treating the overlapping physiological problems that routine blood panels miss. Even when a patient already has a normal thyroid panel, a normal brain MRI, and negative autoimmune screens, 6 specific areas regularly turn up actionable findings:

1. Orthostatic intolerance and the 10-minute NASA Lean Test

Orthostatic intolerance, symptoms that appear when you are upright and improve when you lie back down, is the single highest-yield domain to test because roughly 86% of ME/CFS patients report orthostatic symptoms and identifiable POTS marks a subgroup with targeted, effective treatments. A quick seated blood pressure check in an exam room misses it every time.

The test to run is a morning 10-minute NASA Lean Test. You lie flat and quiet for 5 to 10 minutes to establish a baseline heart rate and blood pressure, then stand with your shoulder blades resting against a wall and your heels 6 inches out, recording heart rate and blood pressure every 1 to 2 minutes for a full 10 minutes. In a 2020 hemodynamic study of the 10-minute NASA Lean Test in ME/CFS, at least 5 minutes of quiet standing were required to catch the circulatory drop. We look for 3 distinct patterns:

• Orthostatic tachycardia (POTS): a sustained heart-rate rise of 30 beats per minute or more over at least 2 readings, with upright symptoms and without a sudden drop in blood pressure. (See our case walkthrough on dizziness and a racing heart when standing.)
• Orthostatic hypotension: a drop of at least 20 mmHg in systolic blood pressure or at least 10 mmHg in diastolic blood pressure.
• Orthostatic hypocapnia: a drop in exhaled carbon dioxide (end-tidal CO2 of 32 mmHg or lower on capnography) while standing. In Natelson's 2022 physiological assessment of ME/CFS, orthostatic hypocapnia - hyperventilating slightly when upright because reduced blood return to the brain triggers a breathing reflex, which then narrows brain blood vessels and causes brain fog - was more common and persistent than POTS itself. A clue often hides on a routine metabolic panel: a serum bicarbonate running low-normal (around 18 to 21 mEq/L) alongside a high-normal albumin (around 5.0 g/dL) can point toward contracted plasma volume and kidney compensation for chronic upright hypocapnia.

When the lean test is positive, treatment follows the stepwise algorithm outlined in the 2026 JAMA review of POTS. First-line care is non-pharmacologic volume expansion: 2 to 3 liters of fluid and 10 to 12 grams of salt daily, paired with waist-high compression garments providing at least 30 mmHg of pressure. Waist-high tights or an abdominal binder are essential because blood pools in the thighs and the abdomen; knee-high socks leave the largest reservoir untouched, and lower-body compression cut standing heart-rate rise from 39 to 23 beats per minute in crossover testing.

When non-pharmacologic steps are not enough, medication choice has to match your resting blood pressure and your fatigue. Many ME/CFS patients run a low baseline blood pressure, around 100/70 mmHg, and beta-blockers like propranolol frequently worsen fatigue when blood pressure is already soft (Zadourian et al., 2018). Two targeted alternatives fit much better:

• Midodrine (starting at 2.5 mg 3 times daily and titrated upward), an alpha-1 agonist that gently squeezes peripheral blood vessels to push blood back to the heart and brain, making it a logical first choice when systolic blood pressure runs under 105 mmHg (Bryarly et al., 2019 JACC).
• Ivabradine (2.5 to 5 mg twice daily), which slows the heart's pacemaker current directly without lowering blood pressure or causing beta-blocker fatigue. Across Taub's 2021 randomized trial in JACC, a 2026 randomized crossover trial comparing ivabradine, propranolol, and placebo, and a 2026 systematic review and meta-analysis, ivabradine lowered standing heart rate by an average of 18.5 beats per minute while tending to support systolic blood pressure.

2. Iron stores without anemia (Ferritin)

You can have normal hemoglobin on a complete blood count (CBC) and still have depleted iron stores dragging down your muscle recovery, cellular energy, and sleep. Whenever a patient has fatigue, menstruates, or describes restless legs at night, we check serum ferritin alongside a current CBC. While many labs flag ferritin only when it falls below 12 or 15 ug/L, our clinical target for fatigue and restless legs and brain iron is a ferritin of at least 50 to 75 ug/L. Repleting iron when ferritin is under that mark is one of the simplest, lowest-risk ways to lift the baseline (see our fatigue workup case guide).

3. Proper celiac serology

When someone has a personal history of autoimmune thyroid disease (like Graves' disease or Hashimoto's thyroiditis), years of digestive symptoms, and chronic fatigue, celiac disease belongs on the checklist. It must be tested in the blood with tissue transglutaminase IgA (tTG-IgA) plus a total serum IgA level while eating gluten. Stool "anti-gliadin" markers sold on commercial microbiome panels do not diagnose or rule out celiac disease. (If you have already cut out gluten, read our guide on celiac testing after going gluten-free.)

4. In-lab sleep testing for upper-airway resistance

Unrefreshing sleep is part of the core criteria for ME/CFS, and a treatable breathing disorder can still hide inside it. Many patients sleep through the night and have a body mass index where doctors never think of sleep apnea, yet they wake with a dry mouth, clenched teeth (bruxism), or a dull morning headache. That pattern can come from upper-airway resistance syndrome (UARS), where narrowed nasal or throat passages make your chest work harder for every breath and fragment deep sleep without causing the full oxygen drops that a home sleep ring or home apnea test requires to score an event. When snoring, tooth grinding, or morning headaches are present, an in-lab polysomnogram (PSG) is the test that catches what home sleep studies miss.

5. Giving low-dose naltrexone (LDN) a complete titration trial

Many patients with ME/CFS have tried low-dose naltrexone (LDN) at 0.5 mg, felt wired or had vivid dreams when they tried to jump to 1.0 or 1.5 mg, and concluded they could not tolerate it. In clinical practice and in a 2026 narrative review of LDN evidence, 0.5 mg is usually below the working dose; the therapeutic window is typically 1.5 to 4.5 mg daily. The best ME/CFS cohort data we have (a retrospective study of 218 patients) found 73.9% of patients reporting symptom improvement on LDN, though a definitive randomized trial in ME/CFS is still pending.

When capsule steps are too steep, two simple adjustments rescue the trial:

• Switch to compounded liquid naltrexone, advancing by tiny steps of 0.25 to 0.5 mg every 2 to 3 weeks (Bruun et al., 2021; Marcus et al., 2023).
• Move the dose from bedtime to the morning if vivid dreams or lighter sleep were the limiting side effect.

6. Vitamin D optimization

In a condition that keeps people indoors and out of the sun, vitamin D routinely runs in the 20s ng/mL. Consistent daily supplementation to bring 25-hydroxyvitamin D toward roughly 50 to 70 ng/mL supports muscle and immune function without needing frequent blood draws along the way.

What tests and treatments are not worth chasing?

Part of protecting a patient with ME/CFS is protecting their energy and their budget from tests that do not change the plan. Two common functional-medicine detours regularly add cost without moving the needle:

• Dried-urine hormone panels ("low cortisol" on a DUTCH test). When a morning blood cortisol level (for example, an 8 AM serum cortisol above 10-12 ug/dL with a normal ACTH) has already ruled out true adrenal insufficiency, a dried-urine curve showing "low free cortisol" does not mean your adrenal glands are failing. Clinical trials of low-dose hydrocortisone in ME/CFS produced minimal fatigue benefit at the cost of adrenal suppression and metabolic side effects. Similarly, low urine DHEA or testosterone readings in women do not translate into a fatigue treatment; female testosterone therapy has evidence only for hypoactive sexual desire disorder and does not improve post-viral fatigue. And if you drink an "adrenal cocktail" of orange juice, sea salt, and cream of tartar that makes you feel steadier in the morning, keep it if you like it, and recognize what it is doing: it works as a salt-and-potassium fluid load supporting low blood volume.
• Broad stool microbiome panels (such as GI-MAP). Finding a borderline commensal bacteria level or a high fecal secretory IgA when calprotectin, pancreatic elastase, and occult blood are normal does not change ME/CFS management, and antimicrobial herb protocols often provoke crashes without helping fatigue.

What belongs in the experimental tier after the basics are done?

Only after pacing is in place and the 6 high-yield contributors above have been tested and treated do we talk about the experimental tier. Every option in this tier is off-label and rests on smaller studies, so we walk through the evidence grade together and test 1 change at a time:

1. Pyridostigmine (Mestinon). Among off-label medications, pyridostigmine has the strongest physiological evidence in ME/CFS, particularly when orthostatic intolerance is part of the picture. Many ME/CFS patients have preload failure: when they stand or exercise, their veins fail to squeeze enough blood back to the right side of the heart, so cardiac output drops. In a 2022 randomized, placebo-controlled invasive cardiopulmonary exercise trial of 45 ME/CFS patients in Chest, a single dose of pyridostigmine significantly increased peak oxygen uptake (VO2), cardiac output, and right atrial filling pressure compared with placebo (Joseph et al., 2023). A 2025 study in Frontiers in Neuroscience also found that pyridostigmine improved hand-grip strength recovery in ME/CFS. It is typically started at 30 mg 3 times daily and titrated toward 60 mg 3 times daily, and because it stimulates acetylcholine in the gut as well as vascular nerves, its main side effect of increased gut motility can be a welcome bonus for patients who struggle with slow digestion.
2. Creatine monohydrate (5 to 8 grams daily). A 2025 7-Tesla magnetic resonance spectroscopy study in Molecular Psychiatry demonstrated altered brain and muscle bioenergetics in ME/CFS and long COVID, and a small 8-week randomized trial of creatine-glucose supplementation in long COVID improved tissue creatine levels and reduced fatigue and concentration symptoms. While a 2023 meta-analysis found a memory signal in healthy adults, the European Food Safety Authority's 2024 review concluded that a cause-and-effect relationship for cognitive function is not yet established. Because creatine is inexpensive and well tolerated, a 2-month trial is a low-risk option.
3. Coenzyme Q10 (200 to 400 mg daily) and NADH (10 to 20 mg daily). Both cofactors sit directly in the mitochondrial electron transport chain. In a 2025 systematic review of 9 ME/CFS supplementation trials in Nutrients, NADH (10 to 20 mg daily) improved fatigue across all 3 randomized controlled trials, and CoQ10 improved fatigue in 4 of 6 trials, whereas generic multivitamins consistently failed. Dose matters: the negative CoQ10 trials used lower doses (72 to 150 mg daily), while responder trials used 200 to 400 mg daily. This mitochondrial vulnerability may have a genetic floor in a subset of patients: a 2025 whole-genome sequencing study in the Journal of Translational Medicine found that nearly 40% of studied ME/CFS participants carried rare monogenic variants affecting cellular energy and fatty-acid oxidation (which specifically predicted severe infection-triggered crashes), ion transport, red blood cell stability, or muscle stability.
4. H1 and H2 antihistamines. When a patient has symptoms of mast cell activation - flushing, hives, itching, or predictable reactions after high-histamine meals (Castells et al., 2024) - a 4-week trial of a non-sedating H1 blocker (like cetirizine or fexofenadine) paired with an H2 blocker (famotidine) is reasonable. Without mast cell symptoms, we skip it, because the only randomized controlled trial of an antihistamine in unselected chronic fatigue syndrome was negative.
5. Low-dose aripiprazole (0.25 to 2 mg daily). Used off-label in some specialty clinics for neuroinflammation and severe brain fog, low-dose aripiprazole rests on retrospective case series and expert consensus documents with zero randomized trials to date, and it can cause restlessness, weight gain, or sleep disruption. It stays at the back of the line.

When should you see a doctor right away?

Seek urgent or same-day medical evaluation if new or worsening symptoms point outside of ME/CFS, even when you have lived with chronic fatigue for years. Red flags that need prompt assessment include:

• Fainting (syncope), chest pain, or new shortness of breath at rest
• New weakness on one side of the face or body, slurred speech, or double vision
• Unexplained fevers, drenching night sweats, or unintentional weight loss
• Severe difficulty swallowing or weakness that worsens rapidly as you chew or speak
• Heart palpitations accompanied by dizziness that does not resolve when lying flat

How does Fishtown Medicine approach ME/CFS and post-exertional malaise?

At Fishtown Medicine, our chronic fatigue and POTS care is built so the medical visit itself never causes a crash. Travel, fluorescent waiting rooms, and repeating a 5-year medical history from scratch all spend energy you need for recovery (Latimer et al., 2023). If you have told your story 10 times already, you do not have to write it an 11th: share what you have the bandwidth for, upload the PDFs or specialty notes you already hold, and once you connect, our team requests the remaining records on your behalf. Dr. Ash reads the whole file before your first conversation so you start at the plan.

Because Fishtown Medicine is a telemedicine-first practice - combining unhurried video visits, asynchronous record review, and direct text access when you have a question or want to review your morning 10-minute NASA Lean Test numbers - we sequence your workup inside your energy envelope. That step-by-step pacing of care is part of how our strategic roadmap applies the Pillars of Medicine 3.0 to complex chronic illness:

1. Weeks 1 to 2 (Stabilize the envelope): Stop fixed-increment exercise plans, set your initial heart-rate ceiling (Resting HR + 15 bpm) on a chest-strap monitor, and run the missing high-yield checks (morning 10-minute lean test, ferritin and CBC, tTG-IgA and total IgA, and a sleep architecture review).
2. Weeks 3 to 6 (Treat what we find): Start volume support (2-3 liters fluid, 10-12 grams salt, waist-high 30 mmHg compression) and blood-pressure-matched therapy (midodrine or ivabradine) when orthostatic intolerance is present; replete iron toward a ferritin above 50-75 ug/L; and begin a slow liquid LDN titration (0.25-0.5 mg steps every 2-3 weeks). When a finding needs an in-lab sleep study or autonomic neurology testing for small fiber neuropathy, we coordinate the referral and both results come back to Dr. Ash, who reads every one himself.
3. Weeks 8 to 12 (Measure whether the ceiling is rising): Re-check ferritin, review morning resting heart rate, step counts, and autonomic symptom scores (Barr et al., 2026), and only expand daily activity once you have been stable inside your envelope without crashes.

If you want a physician who knows the difference between graded exercise and energy-envelope pacing, start your intake at Fishtown Medicine.

Related at Fishtown Medicine

• When You Never Got Better: Long COVID & Post-Viral Illness - the starting framework for post-infectious syndromes
• The POTS & Dysautonomia Strategy - volume expansion, compression, and subtype-matched medications
• Dizziness and a Racing Heart When You Stand: When to Think About POTS - how the 10-minute stand test works in practice
• Low-Dose Naltrexone (LDN): A Physician's Guide - mechanism, dosing, and titration
• Restless Legs and Brain Iron - why ferritin targets sit higher than standard lab cutoffs
• Tired for Months, Labs "Normal": The Fatigue Workup That Found It - the foundational primary care differential

Scientific References

1. National Institute for Health and Care Excellence (NICE). "Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management." NICE Guideline NG206. October 2021. NICE
2. Geraghty K, Hann M, Kurtev S. "Myalgic encephalomyelitis/chronic fatigue syndrome patients' reports of symptom changes following cognitive behavioural therapy, graded exercise therapy and pacing treatments: Analysis of a primary survey compared with secondary surveys." Journal of Health Psychology. 2019;24(10):1318-1333. DOI
3. Brown M, Khorana N, Jason LA. "The role of changes in activity as a function of perceived available and expended energy in nonpharmacological treatment outcomes for ME/CFS." Journal of Clinical Psychology. 2011;67(3):253-260. DOI
4. Nelson MJ, Bahl JS, Buckley JD, Thomson RL, Davison K. "Evidence of Altered Cardiac Autonomic Regulation in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review and Meta-Analysis." Medicine (Baltimore). 2019;98(43):e17600. PubMed
5. Walitt B, Singh K, LaMunion SR, et al. "Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome." Nature Communications. 2024;15:907. DOI
6. Joseph P, Pari R, Miller S, et al. "Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Placebo-Controlled Trial of Pyridostigmine." Chest. 2022;162(5):1116-1126. PubMed
7. Natelson BH, Lin JS, Blate M, et al. "Physiological Assessment of Orthostatic Intolerance in Chronic Fatigue Syndrome." Journal of Translational Medicine. 2022;20(1):95. PubMed
8. Lee J, Vernon SD, Jeys P, et al. "Hemodynamics During the 10-Minute NASA Lean Test: Evidence of Circulatory Decompensation in a Subset of ME/CFS Patients." Journal of Translational Medicine. 2020;18(1):314. PubMed
9. Jason L, Benton M, Torres-Harding S, Muldowney K. "The Impact of Energy Modulation on Physical Functioning and Fatigue Severity Among Patients With ME/CFS." Patient Education and Counseling. 2009;77(2):237-241. PubMed
10. Casson S, Jones MD, Cassar J, et al. "The Effectiveness of Activity Pacing Interventions for People With Chronic Fatigue Syndrome: A Systematic Review and Meta-Analysis." Disability and Rehabilitation. 2023;45(23):3788-3802. PubMed
11. Sanal-Hayes NEM, Mclaughlin M, Hayes LD, et al. "A Scoping Review of 'Pacing' for Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Lessons Learned for the Long COVID Pandemic." Journal of Translational Medicine. 2023;21(1):720. PubMed
12. Keller B, Receno CN, Franconi CJ, et al. "Cardiopulmonary and Metabolic Responses During a 2-Day CPET in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Translating Reduced Oxygen Consumption to Impairment Status to Treatment Considerations." Journal of Translational Medicine. 2024;22(1):627. PubMed
13. Aitken A, Sawyer A, Iwasaki A, et al. "Digital physiological biomarkers predict within-person symptom changes in complex chronic illness." NPJ Digital Medicine. 2026. DOI
14. Rekeland IG, Sorland K, Bruland O, et al. "Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients." PLoS One. 2022;17(9):e0274472. PMC
15. Sanal-Hayes NE, Hayes LD, Mair JL, et al. "A digital platform with activity tracking for energy management support in long COVID: a randomised controlled trial." Nature Communications. 2026. DOI
16. Natelson BH, Brunjes DL, Mancini D. "Chronic Fatigue Syndrome and Cardiovascular Disease: JACC State-of-the-Art Review." Journal of the American College of Cardiology. 2021;78(10):1056-1067. PubMed
17. Chung TH, Raj SR. "Postural Orthostatic Tachycardia Syndrome (POTS): A Review." JAMA. 2026. JAMA
18. Bryarly M, Phillips LT, Fu Q, Vernino S, Levine BD. "Postural Orthostatic Tachycardia Syndrome: JACC Focus Seminar." Journal of the American College of Cardiology. 2019;73(10):1207-1228. PubMed
19. Taub PR, Zadourian A, Lo HC, et al. "Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome." Journal of the American College of Cardiology. 2021;77(7):861-871. PubMed
20. Uppal J, Deol P, Giri P, et al. "A Randomized Crossover Trial of Ivabradine, Propranolol, and Placebo in Postural Orthostatic Tachycardia Syndrome: A Detailed Description." JACC: Advances. 2026. PubMed
21. Kumar V, Qadri SH, Nardelli da Silva AB, et al. "Ivabradine in the Treatment of POTS Before and After COVID-19 Pandemic: A Systematic Review and Meta-Analysis." Journal of Cardiovascular Pharmacology. 2026. PubMed
22. Gouda AHK, Aitcheson NEC, Steadman KJ. "Low-Dose Naltrexone: What is the Evidence? A Narrative Review." Advances in Therapy. 2026. DOI
23. Poliwoda S, Noss B, Truong GTD, et al. "The Utilization of Low Dose Naltrexone for Chronic Pain." CNS Drugs. 2023;37(8):663-670. DOI
24. Godlewska BR, Sylvester AL, Emir UE, et al. "Brain and muscle chemistry in myalgic encephalitis/chronic fatigue syndrome (ME/CFS) and long COVID: a 7T magnetic resonance spectroscopy study." Molecular Psychiatry. 2025. DOI
25. Schlomer E, Stein E, Kedor C, et al. "Pyridostigmine Improves Hand Grip Strength in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome." Frontiers in Neuroscience. 2025. PubMed
26. Slankamenac J, Ranisavljev M, Todorovic N, et al. "Eight-Week Creatine-Glucose Supplementation Alleviates Clinical Features of Long COVID." Journal of Nutritional Science and Vitaminology. 2024;70(2):174-178. PubMed
27. Dorczok MC, Mittmann G, Mossaheb N, et al. "Dietary Supplementation for Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Systematic Review." Nutrients. 2025;17(3):475. PubMed
28. Birch CL, Wilk BM, Gajapathy M, et al. "Uncovering the genetic architecture of ME/CFS: a precision approach reveals impact of rare monogenic variation." Journal of Translational Medicine. 2025;23(1):1412. PubMed